Cartalax (20mg) Research Peptide: An AED Tripeptide for Cartilage, Joint & Extracellular Matrix Studies

If your research investigates cartilage biology, joint health, or the molecular mechanisms of connective tissue repair, Cartalax (20mg) research peptide — also known as the AED tripeptide (Ala-Glu-Asp) or T-31 — offers a precisely defined synthetic tool with a growing body of scientific literature. Belonging to the Khavinson family of peptide bioregulators, Cartalax is a short-chain synthetic peptide derived from a natural protein fragment found in healthy cartilage.

It is specifically designed to target biological pathways involved in cellular aging, inflammation, and tissue repair. Cartalax has been shown to upregulate genes involved in cartilage matrix synthesis, support collagen and proteoglycan production, and downregulate genes associated with cartilage degradation. This makes Cartalax (20mg) research peptide a valuable tool for laboratories investigating osteoarthritis, connective tissue biology, extracellular matrix (ECM) dynamics, and the fundamental processes of cellular aging.

At Wuhan Top Miracle Peptides, we supply high‑purity Cartalax (20mg) research peptide to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to ≥98% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into cartilage repair, joint health, and connective tissue biology begin with uncompromising quality.

What Is Cartalax and How Does It Work?

To fully appreciate the research potential of Cartalax (20mg) research peptide, it is essential to understand its biochemical identity, its role as a tissue‑specific bioregulator, and the mechanisms by which it exerts its effects.

The AED Tripeptide: A Structural Mimic of Type XI Collagen

Cartalax is a synthetic tripeptide consisting of three amino acids: alanine, glutamic acid, and aspartic acid — the sequence Ala‑Glu‑Asp (AED). Its molecular formula is C₁₂H₁₉N₃O₈, with a molecular weight of approximately 333.29 g/mol.

The peptide’s sequence is derived from the alpha‑1 chain of type XI collagen, a minor fibrillar collagen that plays an essential role in maintaining cartilage integrity. Type XI collagen is involved in organising the fibrillar structure of type II collagen, the primary collagen type found in cartilage. By mirroring a segment of this protein, Cartalax is hypothesised to interact with collagenous matrices, potentially influencing tissue resilience and repair mechanisms.

Mechanism of Action: Multi‑Target Bioregulation

The biological activity of Cartalax (20mg) research peptide is mediated through several intersecting mechanisms:

Cartilage Synthesis and ECM Protection

Cartalax demonstrates an exceptional capacity to enhance tissue anabolic metabolism. It upregulates chondrocyte functional activity, rapidly increasing the synthesis and subsequent secretion of various extracellular matrix components. In vitro studies have confirmed that treated chondrocytes or stem cells show significantly elevated gene expression levels of type II collagen and aggrecan, with corresponding increases in the actual production of said proteins. Additionally, Cartalax inhibits the synthesis of MMP‑9, an enzyme involved in ECM remodelling whose increased activity is associated with aging in fibroblasts. It suppresses pro‑inflammatory cytokine‑induced MMPs and ADAMTS, mitigating the direct erosion and degradation of type II collagen and proteoglycans.

Fibroblast Proliferation and Anti‑Apoptotic Effects

Cartalax may contribute to the proliferation of fibroblasts, as suggested by its potential enhancement of Ki‑67 expression, a well‑known marker associated with cell proliferation. It has also been shown to suppress caspase‑3 activity, indicating its potential to inhibit apoptosis (programmed cell death), thereby potentially contributing to an extended cellular lifespan. The peptide “reduced the level of apoptosis in young and aged cultures”. It also increases the expression of CD98hc, which is implicated in the regeneration and aging processes of cells.

Senescence Marker Reduction and SIRT6 Upregulation

Research involving renal epithelial cell cultures has suggested a reduction in the expression of senescence‑associated proteins such as p16, p21, and p53 upon exposure to Cartalax. Additionally, there are observations of increased expression of SIRT6, a sirtuin linked to longevity and genomic stability. This upregulation may imply a role for Cartalax in enhancing cellular repair mechanisms and resilience to stress.

Anti‑Inflammatory and Immunomodulatory Effects

Cartalax actively suppresses, or at least reduces, NF‑κB expression — a key signal for activating numerous inflammatory factors. This effectively alleviates the pain, swelling, and stiffness associated with inflammation.

Key Research Applications for Cartalax (20mg)

Cartalax (20mg) research peptide is a versatile tool with applications spanning several domains of biomedical research.

1. Cartilage & Osteoarthritis Research

As a peptide that upregulates genes involved in cartilage matrix synthesis and downregulates genes associated with cartilage degradation, Cartalax is a valuable tool for studying osteoarthritis and cartilage biology. Research applications include:

• Chondrocyte Activity: Investigating how Cartalax influences chondrocyte function and extracellular matrix regulation.

• Collagen and Proteoglycan Production: Studying the peptide’s ability to support the synthesis of type II collagen and aggrecan.

• Cartilage Degradation: Exploring how Cartalax inhibits MMPs and ADAMTS to preserve cartilage integrity.

• Osteoarthritis Models: Investigating the peptide’s effects in animal models of osteoarthritis and joint degeneration.

2. Fibroblast & Connective Tissue Research

Cartalax’s effects on fibroblast proliferation and apoptosis make it a valuable tool for studying connective tissue biology. Research applications include:

• Fibroblast Proliferation: Investigating how Cartalax enhances Ki‑67 expression and promotes fibroblast growth.

• Apoptosis Studies: Exploring how Cartalax suppresses caspase‑3 activity and reduces apoptosis in aging cell cultures.

• ECM Remodelling: Studying how Cartalax inhibits MMP‑9 synthesis to preserve ECM integrity.

• Cellular Senescence: Investigating the peptide’s ability to reduce p16, p21, and p53 expression.

3. Cellular Aging & Senescence Research

Cartalax has demonstrated effects on markers associated with cellular senescence, making it a valuable tool for aging research. Research applications include:

• Senescence Markers: Studying how Cartalax reduces the expression of p16, p21, and p53.

• SIRT6 Upregulation: Investigating the peptide’s ability to increase SIRT6 expression and its implications for longevity and genomic stability.

• Mitochondrial Function: Exploring how Cartalax may support mitochondrial function by modulating stress response pathways.

• Cellular Lifespan: Investigating the peptide’s potential to extend cellular lifespan and combat age‑related decline.

4. Inflammation & Immunomodulation Research

Cartalax’s anti‑inflammatory and immunomodulatory properties make it a valuable tool for studying inflammatory signalling. Research applications include:

• NF‑κB Signalling: Investigating how Cartalax suppresses NF‑κB expression and reduces inflammatory responses.

• Cytokine Modulation: Studying the downregulation of pro‑inflammatory cytokine‑induced MMPs and ADAMTS.

• Immunomodulation: Exploring the peptide’s broader immunomodulatory effects.

Chemical & Physical Specifications

Accurate characterisation of Cartalax (20mg) research peptide is essential for reproducible experimental design.

Reconstitution & Handling Protocol for Cartalax (20mg)

Proper reconstitution of Cartalax (20mg) research peptide is critical for maintaining its structural integrity and biological activity.

Step 1 – Preparation

• Bring the sealed Cartalax vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the Cartalax vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 20 mg per 2 mL of diluent, yielding a 10 mg/mL stock solution.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted Cartalax into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles, as peptides are susceptible to degradation.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table

Adjust diluent volume based on your experimental requirements. For cell culture applications, typical working concentrations may range from 0.1‑10 µM.

Storage & Stability Guidelines

Why Choose Wuhan Top Miracle Peptides for Cartalax (20mg)?

As an authentic licensed peptide supplier based in the United Kingdom, we supply Cartalax (20mg) research peptide and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed ≥98% for every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• UK‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO).

Researchers across the United Kingdom—including those at leading institutions in London, Cambridge, Oxford, Manchester, and Edinburgh—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: Cartalax (20mg) Research Peptide

What is Cartalax (20mg) research peptide?
Cartalax (AED, T‑31) is a synthetic tripeptide (Ala‑Glu‑Asp) belonging to the Khavinson family of peptide bioregulators. It is derived from a natural protein fragment found in healthy cartilage and is used in research to study cartilage biology, connective tissue repair, inflammation, and cellular aging.

What is the sequence and molecular weight of Cartalax?
The sequence is Ala‑Glu‑Asp (AED). Its molecular formula is C₁₂H₁₉N₃O₈, and its molecular weight is approximately 333.29 g/mol.

What are the primary research applications for Cartalax?
Cartalax is used in cartilage and osteoarthritis research (chondrocyte activity, collagen and proteoglycan production), fibroblast and connective tissue research (proliferation, apoptosis, ECM remodelling), cellular aging and senescence research (senescence markers, SIRT6 upregulation), and inflammation and immunomodulation research.

What is the mechanism of action of Cartalax?
Cartalax upregulates genes involved in cartilage matrix synthesis, supports collagen and proteoglycan production, downregulates genes associated with cartilage degradation, inhibits MMP‑9 synthesis, suppresses caspase‑3 activity, reduces senescence markers (p16, p21, p53), upregulates SIRT6, and suppresses NF‑κB expression.

 What purity does your Cartalax (20mg) meet?
Our Cartalax is tested to ≥98% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

How should I reconstitute Cartalax (20mg)?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake. A typical starting concentration is 10 mg/mL.

How should I store reconstituted Cartalax?
Reconstituted Cartalax should be stored at 2‑8°C for short‑term use. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

Is Cartalax research peptide legal to purchase in the UK?
Yes. Cartalax is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United Kingdom for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: Cartalax has been developed in Russia and has been studied in preclinical settings; it is not registered as a medicinal product with regulatory agencies such as the MHRA, EMA or FDA.

Does Wuhan Top Miracle Peptides ship internationally?
Yes. We ship across the EU (France, Germany, Spain, Sweden, Italy) and to the USA from our UK warehouse. Wholesale pricing is available for bulk orders.

Wholesale Cartalax 20mg Supply Across the UK and Europe

Wuhan Top Miracle Peptides supports wholesale peptide buyers in the United Kingdom and international markets.

We Support Enquiries From:

• United Kingdom
• France
• Germany
• Spain
• Sweden
• Italy
• USA
• Wider Europe

For larger Cartalax 20mg enquiries, contact our team before ordering. This helps confirm stock, documentation, shipping options, product identity, and buyer verification requirements.

Where to Source Cartalax 20mg in the UK

If you are searching for where to source Cartalax 20mg in the UK, Wuhan Top Miracle Peptides provides a simple professional enquiry process.

Professional Enquiry Process

1. Review the Cartalax 20mg product details.
2. Check the current label and batch information.
3. Confirm whether the batch is listed as Cartalax, AED, Ala-Glu-Asp, or another verified identity.
4. Ask about COA and purity-related documentation.
5. Confirm the sequence and salt form where required.
6. Confirm CAS number and storage notes where required.
7. Confirm your shipping country.
8. Discuss wholesale quantity requirements.
9. Complete buyer verification where required.
10. Place a professional enquiry with support from our team.

 

Bulk Peptides Page
Shipping & Returns Page
Contact Us Page
Shop Page
Quality / Compliance Page
Chonluten Product Page
Cortagen Product Page
Scientific or compound reference source
Scientific or peptide reference source
Official UK medicine advertising guidance
Google Search Central
ASA / CAP Code Section 12

From its origin as a synthetic tripeptide derived from type XI collagen to its well‑characterised role in upregulating cartilage matrix synthesis, inhibiting ECM degradation, and modulating cellular senescence markers, Cartalax (20mg) research peptide provides a precisely defined and increasingly valuable platform for advanced cartilage and connective tissue research.

Its ability to promote chondrocyte activity, support collagen and proteoglycan production, reduce senescence markers, and suppress inflammatory signalling—supported by peer‑reviewed research published in the Bulletin of Experimental Biology and Medicine and other authoritative journals—makes it a valuable addition to any laboratory investigating osteoarthritis, cartilage biology, connective tissue repair, or the molecular mechanisms of cellular aging. By choosing high‑purity, lab‑verified Cartalax (20mg) research peptide from Wuhan Top Miracle Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with Cartalax (20mg)? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade Cartalax delivered directly to your facility in the UK, EU, or USA.